Cyclins D 1 (cD 1 ) and E (cE) are G 1 phase cyclins believed to participate in the pathogenesis of malignancy. Overexpression of cD 1 has been reported to influence prognosis in squamous cell carcinomas (SCC) of the larynx, but was not significant in a limited study of non-small cell lung cancers (NSCLC). Altered expression of cE has been proposed as another potential prognostic marker in malignancy but its possible role in NSCLC has not been elucidated. In order to determine the prognostic value of cD 1 and cE in NSCLC, paraffinembedded sections of 467 NSCLC were immunostained with monoclonal antibody to cD 1 (1:500, PharMingen, San Diego, CA) and 400 NSCLC with MA to cE (1:2500, PharMingen) using an enhanced sensitivity avidin-biotin complex technique. The number of tumor cells with nuclear and/or cytoplasmic immunopositivity was graded on a scale of: 0 ‫؍‬ less than 1%, 1 ‫؍‬ 1 to 10%, 2 ‫؍‬ 10 to 25%, 3 ‫؍‬ 25 to 50%, 4 ‫؍‬ 50 to 75%, 5 ‫؍‬ more than 75%. Results were correlated with survival by KaplanMeier survival plot using Stat-View software (Abacus Concepts, Berkeley, CA). Overall, 426 NSCLC with cD 1 and 360 NSCLC with cE had adequate follow-up (median, 76 mo) for survival analysis. Both cyclins independently showed significance in prognosis of SCC but not other cell types. For cD 1 , absence of immunostaining was associated with worse prognosis than any immunopositivity for all stages of SCC (P ‫؍‬ .025). For cE, Stage I and II SCC with less than 50% immunopositivity had a worse prognosis (P ‫؍‬ .029). Of 70 Stage I and II SCC immunostained for both monoclonal antibodies, 55% of patients with tumors that demonstrated both absence of cD 1 staining and cE immunopositivity in less than 50% of cells were dead at 5 years compared to 35% of patients with tumors that demonstrated positive staining with cD 1 and cE immunopositivity in more than 50% of cells. These results strongly suggest cD 1 and cE can independently predict prognosis in early stage SCC. Worse prognosis was associated with loss of expression, consistent with mechanisms other than overexpression of these cyclins in the progression of SCC.
Lung cancer is now the leading cause of cancer deaths in both men and women in the United States (1) . Histologically, lung cancer can be classified into one of four major subtypes: adenocarcinoma (AC), squamous cell carcinoma (SCC), large cell carcinoma (LC), and small cell carcinoma. Whereas small cell lung cancers have a uniformly aggressive clinical picture, non-small cell carcinomas (NSCLC) are a heterogeneous group of tumors with variable clinical courses. Therefore, the detection of prognostic markers is essential in order to specify treatment protocols and determine which patients need more aggressive surgery, adjuvant chemotherapy, or radiotherapy.
Studies have reported alterations of protooncogenes and tumor suppressor genes that may contribute to the progression of NSCLC and serve as potential prognostic markers. Cyclins D 1 and E are relatively recently described proteins implicated in the pathogenesis of NSCLC. Cyclins (primarily D 1 , D 2 , D 3 , and E) and their associated cyclindependent kinases regulate progression of the cell cycle through the G 1 phase and into the S-phase of DNA replication (2) . Overexpression of cD 1 and cE has been demonstrated to shorten the G 1 phase of the cell cycle (3, 4) . Increased expression of cyclin D 1 (cD 1 ), as a result of amplifications and rearrangements, has been reported in parathyroid adenomas (5); some B-cell lymphomas (6) ; and in esophageal (7), head and neck (8, 9) , hepatic (10, 11) , colorectal (12) , and some breast carcinomas (13) (14) (15) . These studies have suggested that overexpression of cD 1 shortens the G 1 phase and accelerates cell growth, thus positively contributing to oncogenesis.
Studies examining the use of immunohistochemical staining for cD 1 or cyclin E (cE) as a potential prognostic marker are extremely rare. Overexpression of cD 1 has been reported to negatively influence prognosis in squamous cell carcinomas (SCC) of the larynx (8), but was of no prognostic value in a limited study of NSCLC (16) and mammary carcinomas (17) . Increased expression of cE, another key regulatory component of cell cycle control, has been demonstrated in colorectal (18) and mammary carcinomas (19) and has been proposed as a potential and possibly better prognostic marker for breast cancer than cyclin D (19) , but its possible role in NSCLC has not been elucidated. Therefore, this study was undertaken to determine the prognostic value of cD 1 and cE in NSCLC.
MATERIALS AND METHODS

cD 1 Patient and Specimen Selection
Paraffin blocks from wedge biopsies and resections (segmentectomies, lobectomies, pneumonectomies) of primary NSCLC for which patient follow-up was available were retrieved from the archives of The Methodist Hospital in Houston, Texas. A total of 467 specimens (5% wedge biopsies, 95% resections) with follow-up were available for study. The series included 270 AC, 130 SCC, and 67 LC. Pathology reports and cancer registry data were reviewed to determine tumor stage.
cD 1 Immunohistochemical Staining
After antigen retrieval by microwave irradiation in citrate buffer, sections were incubated overnight with the antibody used for the detection of cD 1 (purified mouse anti-human cD 1 mAB, clone G124 -326, 1:500, San Diego, CA). Detection was by Vectastain Elite mouse IgG immunoperoxidase kit (Vector, Burlingame, CA). Diaminobenzidine was used as the chromagen, and the sections were lightly counterstained with hematoxylin. With each batch of samples, a positive control (colon) was evaluated.
cE Patient and Specimen Selection
Paraffin blocks from wedge biopsies and resections (segmentectomies, lobectomies, pneumonectomies) of primary NSCLC for which patient follow-up was available were retrieved from the archives of The Methodist Hospital in Houston, Texas. A total of 400 specimens (6% wedge biopsies, 94% resections) with follow-up were available for study. The series included 232 AC, 113 SCC, and 55 LC. Pathology reports and cancer registry data were reviewed to determine tumor stage.
cE Immunohistochemical Staining
After antigen retrieval by microwave irradiation in citrate buffer, sections were incubated overnight with the antibody used for the detection of cE (purified mouse anti-human cE mAB, clone HE12, 1:2500, San Diego, CA). Detection was by Vectastain Elite mouse IgG immunoperoxidase kit (Vector). Diaminobenzidine was used as the chromagen, and the sections were lightly counterstained with hematoxylin. With each batch of samples, a positive control (spleen) was evaluated.
Grading and Statistical Analysis
The number of tumor cells with nuclear and/or cytoplasmic immunopositivity was graded on a scale of: 0 ϭ less than 1%, 1 ϭ 1 to 10%, 2 ϭ 10 to 25%, 3 ϭ 25 to 50%, 4 ϭ 50 to 75%, 5 ϭ more than 75%. Histologic subtype, stage, and percent of tumor cells staining positively were correlated with survival using the Kaplan-Meier method. Significance was tested for by the log-rank (Mantel-Cox) method, and P values less than .05 were considered statistically significant. Stat-View software from Abacus Inc. was used for all statistical analyses.
RESULTS
cD 1 Staining
The patients ranged in age from 35 to 90 years at the time of diagnosis, with a median age of 64.6 years and a mean of 64.5 years. Lung cancer was known to be the primary cause of death in 88 patients. Thirty patients (7%) were nonsmokers. The male to female ratio was 263:163.
The cD 1 cytoplasmic staining results are summarized in Table 1 . Overall, 48% of tumors demonstrated positive staining. The data was further subdivided by histologic subtype, stage, and percent of tumor cells staining positively (Tables 1 and 2 ). The immunostaining pattern was predominantly cyto- plasmic (Fig. 1) ; however, 29 tumors also demonstrated focal nuclear staining. Four hundred twenty-six patients had adequate follow-up for examination by Kaplan-Meier survival analysis. For analysis purposes, follow-up was truncated at 4 years. Of the 426 patients, 96% were followed for at least 4 years. At 4 years, 214 patients were dead, 197 were alive, and 15 had been lost to followup. The only subset that generated a statistically significant P value was the group of all 130 SCC (all stages). This group showed a trend for better survival in cD 1 -positive versus negative tumors (P ϭ .0902). When follow-up was truncated at 5 years, this value dropped to P ϭ .0555; when follow-up was further censored to 4 years, this became statistically significant (P ϭ .0246, Fig. 2 ). The same trend was observed regardless of stage of SCC. No correlation between cytoplasmic staining score and grade or stage was observed. In fact, it was relatively consistent across such categories. Analysis of the 29 tumors that showed focal nuclear staining did not demonstrate a clear relationship to cell type, stage, grade, cytoplasmic staining, smoking history, or prognosis.
cE Staining
The patients ranged in age from 39 to 90 years at the time of diagnosis, with both the median and mean age being 64.2 years. Lung cancer was known to be the primary cause of death in 88 patients. Twenty patients (5.5%) were nonsmokers. The male to female ratio was 230:130.
The overall cE staining results are summarized in Table 3 . Overall, 32% of tumors demonstrated positive staining in more than half of the cells. The data was further subdivided by histologic subtype, stage, and percent of tumor cells staining positively. Table 4 outlines the cE immunostaining results for SCC. The cE immunostain showed intense nuclear staining; no cytoplasmic staining was demonstrated (Fig. 3) .
Three hundred sixty cases had adequate follow-up for examination by Kaplan-Meier survival analysis. Follow-up was not truncated for this study set. Two hundred thirty-nine patients were followed until their death; the remaining 121 patients have been tracked to the present or have been lost to contact. The mean follow-up for these 121 patients was 82.6 mo, with a median of 76 mo. The only subset that generated a statistically significant P value was the group of all 70 stage I and II SCC. This group demonstrated significantly better survival in cases showing immunopositivity in greater than 50% of cells (P ϭ .029, Fig. 4) .
A seemingly contradictory trend was noted for cE positivity in 184 stage I and II AC (including bronchioloalveolar carcinomas). Comparing survival analysis for patients with negatively versus positively staining tumors, absence of staining showed a trend toward better survival (P ϭ .0647). This P value is very close to statistical significance.
Conclusion
The results of our study strongly suggest that cD 1 and cE expression is associated with better prognosis in a human cancer, specifically NSCLC. The expression of cD 1 in our 130 pulmonary SCC demonstrates a trend toward increased patient survival outcome, which was statistically significant only at a relatively short (4 years) follow-up period. Longterm follow-up may achieve statistical significance when applied to a larger series of SCC cases. In early stage SCC, better survival was demonstrated in cases showing immunopositivity for cE in more than 50% of tumor cells. These results were statistically significant. The cD 1 and cE expression provided prognostic significance in SCC, but not tumors of other cell types.
Most of the previous studies involving cD 1 and cE have found overexpression of these cyclins in human tumors from various sites and suggested a link between overexpression and oncogenesis. Knowledge of the cell cycle provides a reasonable expla- nation to support these findings. The retinoblastoma-1 (Rb) tumor suppressor gene produces a protein (pRB) thought to be the major repressor of G 1 phase progression (20) . pRB is active in early G 1 in its hypophosphorylated form; in mid/late G 1 , the protein becomes inactivated by phosphorylation. Cyclins D 1 and E, in association with their catalytic partners, the cyclin-dependent kinases (cdk), are responsible for this phosphorylation of pRB and regulate progression of the cell cycle from G 1 into S-phase (2). The protein product of Rb appears to inhibit cD 1 and cE promotor activity by binding E2F transcription factors. In mid-to-late G1, when pRB is initially phosphorylated, perhaps by cdk-cyclin D complexes, E2F transcription factors are released, which promote transcription of the cD 1 and cE genes (21, 22) . Increased cD 1 and cE expression continues pRB phosphorylation, releasing additional E2Fs that continue cD 1 and cE transcription.
Therefore, it is plausible that overexpression of cD 1 or cE heightens phosphorylation of pRB and promotes cellular proliferation by suppressing pRB activity. This concept of cD 1 and cE as positive regulators of cell proliferation is supported by studies that have demonstrated that microinjection of anticyclin D 1 and E antibodies prevent S-phase entry (3, 23, 24) . The studies that have found overexpression of cD 1 or cE in tumors have postulated that cD 1 and cE are positively involved in tumorigenesis because increased levels of cD 1 and cE have been shown to promote cell growth by shortening the G 1 phase (3, 4) . It is possible then that overexpression of these cyclins may contribute not only to tumorigenesis but also to clinical aggressiveness of a tumor. However, our study has shown that cD 1 and cE immunopositivity confers a better prognosis in human lung cancers, and recent studies have raised the possibility that cD 1 actually functions as a negative regulator of cellular proliferation (3, 4, 25) . We have already established the feedback mechanism between cD 1 , cE, and pRB. Several studies have reported a lack of cD 1 expression in pRB-deficient tumors (21, 26) . The absence of cD 1 in the higher stage tumors in our study may be related to mutations in the Rb-1 gene. It is likely that mutations in Rb-1 gene are more significant than those of the cyclins and further study involving cD 1 and Rb-1 expression in concert is necessary to support this intriguing possibility. Additionally, this concept is supported by Lukas et al. (27) , who reported that microinjection of anti-cyclin D 1 antibodies accelerates S-phase entry in pRB-deficient mouse embryonic fibroblasts. The results of this enticing study are in accord with our findings that suggest lack of cD 1 expression promotes cell proliferation.
Another possible explanation for our findings concerns the amount of cD 1 and the timing at which these levels occur. It has been demonstrated that high levels of cD 1 occurring at the G 1 /S phase junction arrest S-phase entry (3, 23, 28) , suggesting that the amount and timing of cD 1 can exert different effects on cellular proliferation. For unknown reasons, it appears that cD 1 can be either a positive or negative regulator of cellular proliferation in different situations. Additionally, cD 1 has been shown to accumulate in senescent, differentiated cells, which may explain why cD 1 immunopositivity was present in the better-differentiated tumors in our study (29, 30) . In summary, the potential oncogenic properties of cD 1 in vivo are unclear.
Interestingly, our study reveals a seemingly contradictory trend for early stage AC. Tumors showing absence of staining for cE demonstrated a trend toward better survival. This is in agreement with other studies I I  2 5  1  2  3  7  7  5  I I I  2 8  2  3  6  3  7  7  I V  2  0  0  0  1  1  0  Total  113  5  13  21  27 that have demonstrated increased cE expression in increasing grade and stage of AC of the breast (19) . The cyclins and pRB are only two components of a complex regulatory pathway. p16 is a member of a family of regulatory proteins that compete with cD 1 for the binding of cdk 4 and 6 (20) . Cellular growth factors determine the amount of cdk 4 or 6 associated with cD 1 or p16, thereby determining phosphorylation of pRB and cell proliferation. Additionally, cD 1 appears to be regulated by another proto-oncogene, c-myc. Studies have shown Myc can induce cD 1 transcription and that ectopic Myc expression suppresses cD 1 expression in cells that lack functional pRB (25, 31) .
It has been difficult to identify individual cell cycle regulatory proteins to serve as reliable markers for prognosis in human lung cancer because of inconsistencies in studies in the literature. Our findings underscore the need to evaluate more than one protein that may affect the same pathway in order to predict prognosis. Because of these complex interactions, a molecular profile consisting of a battery of potential aberrant proteins for an individual lung cancer may be much more dependable in predicting long-term prognosis.
